Mouse models of prostate cancer: picking the best model for the question

被引:0
作者
Magdalena M. Grabowska
David J. DeGraff
Xiuping Yu
Ren Jie Jin
Zhenbang Chen
Alexander D. Borowsky
Robert J. Matusik
机构
[1] Vanderbilt University,
[2] Meharry Medical College,undefined
[3] University of California Davis,undefined
来源
Cancer and Metastasis Reviews | 2014年 / 33卷
关键词
Mouse models; Prostate cancer; TRAMP; LADY; PTEN; Myc;
D O I
暂无
中图分类号
学科分类号
摘要
When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for “prostate cancer mouse model” yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?
引用
收藏
页码:377 / 397
页数:20
相关论文
共 819 条
[1]  
Miller AB(2012)New data on prostate-cancer mortality after PSA screening New England Journal of Medicine 366 1047-1048
[2]  
Suwa T(2002)Spontaneous lesions in control B6C3F1 mice and recommended sectioning of male accessory sex organs Toxicologic Pathology 30 228-234
[3]  
Nyska A(2009)Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways BJU International 104 438-448
[4]  
Haseman JK(2009)Neuroendocrine differentiation in prostate cancer American Journal of Translation Research 1 148-162
[5]  
Mahler JF(2007)The role of tumor microenvironment in prostate cancer bone metastasis Journal of Cellular Biochemistry 101 873-886
[6]  
Maronpot RR(2004)Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee Cancer Research 64 2270-2305
[7]  
Vis AN(2013)Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee Cancer Research 73 2718-2736
[8]  
Schröder FH(2012)Multipotent and unipotent progenitors contribute to prostate postnatal development Nature Cell Biology 14 1131-1138
[9]  
Sun Y(2011)Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate Molecular Endocrinology 25 1849-1857
[10]  
Niu J(2012)Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation Cancer Cell 21 253-265